Manfredi Rizzo

Manfredi Rizzo

ITALY

 

 

 

 

Prof. Manfredi Rizzo, MD, PhD
Prof. Rizzo studied medicine and got the training in Internal Medicine in Italy. He spent several years in the United States, working at the University of California under the direct supervision of Prof. Ronald M. Krauss. There he was able to perform a number of studies on the patho­‐physiology, metabolism, atherogenicity and clinical properties of plasma lipids and lipoproteins, in patients with different metabolic disorders, including dyslipidemia, diabetes, obesity and the metabolic syndrome.
Prof. Rizzo is Associate Professor of Internal Medicine at the School of Medicine, University of Palermo, Italy with a joint position in the Division of Internal Medicine at the University Hospital, where he is Head of the Unit of Diabetes and Cardiovascular Prevention. Due to his long­‐standing research on metabolic disorders, he has been Invited as Visiting Professor at the Clinic of Endocrinology, Diabetes and Clinical Nutrition, University of Zurich, Switzerland. Also, Dr. Rizzo mantains a Faculty position in the USA, where he is Associate Professor of Internal Medicine at the School of Medicine, University of South Carolina.
Prof. Rizzo sits on the editorial board of 10 international journals with Impact Factor (IF), including Metabolism (IF: 5,777) and BBA­‐Molecular Basis of Disease (IF: 5,476). He has been the recipient of national and international fellowships and awards, and acted as reviewer for 100+ scientific international journals. The research work of Dr. Rizzo combines translational research (focus on the effects and mechanisms of action of lipid­‐lowering and anti­‐diabetic agents) and basic research (focus on novel cardiovascular risk factors), with 200+ scientific publications with Impact Factor (total Impact Factor: >700; H­‐Index: 45). He is ranked n.80 in the list of TOP Italian Scientists Biomedical Sciences (http://www.topitalianscientists.org).
Finally, Prof. Rizzo was the Coordinator of a Panel of European experts who published a Consensus Document on the pathophysiology, atherogenicity and clinical significance of LDL subclasses and, very recently, he has been elected as Executive Board Member of the Mediterranean Group for the Study of Diabetes (MGSD) for the 2­‐year period 2017­‐2019.
Prof. Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine BioMedical Department of Internal Medicine and Medical Specialties School of Medicine, University of Palermo, ITALY